COMMUNIQUÉS West-GlobeNewswire

MMI Receives IDE Approval from FDA for First Robotic Microsurgical Study in Alzheimer’s Patients
05/11/2025
First-of-its-kind study represents the potential for robotic-enabled microsurgical intervention for neurodegenerative diseases, including Alzheimer’s JACKSONVILLE, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- MMI (Medical [...]
Ambio Life Sciences Launches Europe’s First Physician-Led Ibogaine Clinic
05/11/2025
With the opening of its new clinic on Malta’s scenic Mellieha Bay, Ambio becomes the only transcontinental ibogaine provider in the world The clinic responds to high global demand for safe ibogaine treatment with added [...]
Mucinex Brings Mr. Mucus to Canada for the First Time With Proven 12-Hour Cold and Flu Relief
05/11/2025
The germ-loving, cult-favourite Mucinex mascot Mr. Mucus makes his Canadian debut in a coast-to-coast campaign challenging Canadians to kick this seasonal nuisance to the curb TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- [...]
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
05/11/2025
VERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and innovative treatments [...]
MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
05/11/2025
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and [...]
HiFi Solves Consortium Publishes First Major Study Demonstrating the Clinical Research Power of PacBio HiFi Genomes
05/11/2025
New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by short-read sequencing technologies, positioning HiFi as the bridge between research and clinical-grade [...]
CJ Biomaterials signs partnership with BIQ Materials to produce artificial turf infill made with PHACT™ PHA, a certified biodegradable biopolymer, for the European market
05/11/2025
CJ Biomaterials signed an agreement with BIQ Materials, a Swedish biomaterials compounding company, to accelerate the commercialization of PHACT™ PHA-based infill EU ban on intentionally added microplastics including [...]
Alpha Pro Tech, Ltd. Announces Third Quarter 2025 Financial Results
05/11/2025
Overall Third Quarter Sales Increased 3.7% to $14.8 Million, Compared to $14.3 Million for the Third Quarter of 2024 Net sales for the third quarter of 2025 were $14.8 million, up 3.7% compared to $14.3 million for the [...]
Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.
05/11/2025
Company Completes the Required Infrastructure to Support the Introduction of LIBERTY® to the U.S. Market with the Hiring of the Core Commercial Team and Establishing Logistic Partnership Interest and Overwhelmingly [...]
Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update
05/11/2025
BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class 1 targeted and immune-mediated therapeutics to [...]
Normunity announces first patient dosed in Phase 1 clinical study of NRM-823, a T Cell Engager against a novel tumor-specific target, in patients with solid tumors
05/11/2025
Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or metastatic refractory solid tumors NRM-823 is a T cell engager against an [...]
YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring
05/11/2025
Taipei, Taiwan, Nov. 05, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (NasdaqGM: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic [...]
Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
05/11/2025
This strategic filing with the FDA follows encouraging internal data and recent published studies supporting Nexalin’s frequency neurostimulator as a potential non-invasive therapy for cognitive disorders associated [...]
Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia
05/11/2025
TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Fraser Health Research Ethics Board (“REB”) has granted approval [...]
Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease
05/11/2025
Jupiter, Florida, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL ™ , a patented resveratrol-based therapeutic platform targeting [...]
BiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025
05/11/2025
NESS ZIONA, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific [...]
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
05/11/2025
MaxCyte will now host its earnings conference call on November 12, 2025 Management will present at the Stifel Healthcare Conference on November 11, 2025 and Stephens Investment Conference on November 19, 2025 ROCKVILLE [...]
STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update
05/11/2025
HORSHAM, Penn., Nov. 05, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]
Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025
05/11/2025
Company to hold a conference call at 8:00 a.m. ET DURHAM, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative [...]

Pages